Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
复制标题
丙型肝炎病毒基因型 2 或 3 的缩短治疗——是少是多？
DOI：
10.1056/nejme078092
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Liang,TJake
中科院分区：
文献类型：
--
作者：
Liang,TJake
丙型肝炎病毒（HCV）感染是世界范围内慢性肝病、肝硬化和肝癌的一个主要原因，它们共同构成了全球主要的公共卫生负担。自20世纪80年代末引入干扰素- α α单药治疗以来，治疗方法有了实质性的改进，当时的反应率不到10%；现在，聚乙二醇干扰素和利巴韦林联合治疗的成功率约为50%。1,2就像HCV感染的不同结果一样，对治疗的反应也各不相同。与治疗反应相关的重要因素包括种族、年龄、性别、体重以及患者的生化和组织学特征。然而，病毒基因型…
Infection with hepatitis C virus (HCV) is a major worldwide cause of chronic liver disease, cirrhosis, and liver cancer, which together represent a chief global public health burden. Therapy has improved substantially since the introduction of interferon-alfa monotherapy in the late 1980s, when the response rate was less than 10%; now, combination therapy with peginterferon and ribavirin has a success rate of about 50%.1,2Much like the diverse outcomes of HCV infection, the response to treatment varies. Important factors associated with treatment response include the race, age, sex, weight, and biochemical and histologic characteristics of patients. However, viral genotype . . .